ClinicalTrials.gg
RecruitingNCT07206095INTEGRAUpdated Nov 10, 2026

Integrative Diagnosis for SCD and Other RADs

An observational study in Sickle Cell Disease, Thalassaemia and Congenital Dyserythropoietic Anemia (CDA), sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 4 sites in Spain. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 23 studies in Anemia, Sickle Cell with a site in Spain — 8 open to participants now, 12 under way, 5 of them phase 3. Anemia, Sickle Cell · Spain.

Started
2020
with 2 others
Observational
7 of 23
4 open now
Primary completion
2028-12
later than 8 of 11 live
Registered
23rd of 23
by date
Lead sponsor
6 of 23
Hospital Universitari Vall d'Hebron Research Institute

Among the 23 studies in Anemia, Sickle Cell with a site in Spain, this one is one of 3 that started in 2020, is one of 7 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 23rd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

8 of the 23 studies in Anemia, Sickle Cell with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Anemia, Sickle Cell with a site in Spain, or all of them as a file.
02

Study summary

INTEGRA aims at enabling personalized medicine for RADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.

Read the detailed description

Primary objective

INTEGRA aims at enabling personalized medicine for RADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.

Secondary objectives

  • To assess the prognostic value of the newly invented Lorrca® oxygenscan ektacytometer as biomarker providing information of SCD patients severity and response to treatment.
  • To investigate the correlation between Lorrca® parameters and RAD patients genetic and phenotypic characterization.
  • To identify genetic modifiers of RADs both new and previously described as markers for prognosis and clinical course based on genomics approach.
  • To model the progression of RADs in a spleen-like filtering unit using microfluidic technologies to develop a novel diagnostic device for prognosis and patients' stratification. This device will be used for the characterization under flow of rheological and mechanical properties of single RBCs.
  • To establish an innovative algorithm for RADs patient's characterization based on the integration of data generated through the analysis of genetic modifiers and the RBCs rheological/mechanical properties by Lorrca® profiles and microfluidics data in combination with RADs patients' clinical manifestations and treatments.
  • To translate the results on a clinical practice recommendation for management of RADs patients endorsed by European Hematology bodies as ERN-EuroBloodNet and/or the European Hematology Association for its wide dissemination.
  • To disseminate the results obtained among the main target groups: pediatricians, hematologists, public health authorities, and patients' community.
03

Conditions studied

  • Sickle Cell Disease
  • Thalassaemia
  • Congenital Dyserythropoietic Anemia (CDA)
  • Enzyme Disorder; Anemia
  • Spherocytosis, Hereditary
  • Stomatocytosis
  • Hemoglobin Disorder
  • Anemia Due to Membrane Defect
  • Rare Anemia Disorders

Keywords

  • SICKLE CELL DISEASE
  • RARE ANEMIA DISORDERS
  • PERSONALIZED MEDICINE
  • DIAGNOSIS
  • EKTACYTOMETRY
  • registry
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients, all ages, sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia:

Sickle cell disease (SCD) Thalassaemia syndromes Congenital dyserythropoietic anaemia (CDA) Enzymopathies Unstable / altered oxygen affinity Hereditary stomatocytosis Hereditary pyropoikilocytosis

Hereditary spherocytosis (HS), either severe (baseline Hb \<10 g/dL or transfusion-dependent) or with an inconclusive diagnosis:

Patient with chronic haemolytic anaemia and a compatible red cell smear, but with:

EMA binding test: inconclusive or negative Genetic testing: no definitive diagnosis (VUS or no findings)

Exclusion criteria

Exclusion Criteria:

  • Carrier traits in autosomal recessive hereditary anemias
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Interventions

  • GeneticAnalysis of genetic modifiers

    Genetic modifiers for rare anemia disorders will be analyzed through massive sequencing.

  • Diagnostic testDisease phenotyping

    Peripheral blood samples will be used for conventional phenotyping characterization including among others: RBCs morphology, fragility osmotic test, hemoglobin fraction and quantification, hemoglobin stability test, EMA binding test, RBC enzymes quantification assay, RBC rheological properties through Lorrca Maxsis Osmoscan/Oxygescan (Lorrca®)

06

What researchers measure

Primary outcomes

  1. To assess the prognostic value of LoRRca ektacytometry as biomarker providing information of SCD/RADs patients severity

    Severity was assesed as the occurence of: * Vaso-occlusive events (VOEs) in the last 24 months * Kidney injury (defined according to KDIGO guidelines) * Retinopathy (defined as proliferative and non proliferative)

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. To investigate the correlation between LoRRca ektacytometry parameters and SCD/RADs patients genetic and phenotypic characterization.

    Genomic data will be generated using a targeted next-generation sequencing (tNGS) approach. Means, medians, standard deviations (SD), ranges and percentages were calculated using SPSS software (version 20, IBM SPSS Statistics, Chicago, IL, USA). Spearman's rank correlation was used to assess associations between variables. For comparing variables with two categories, either a student's t-test or a Mann-Whitney U test was performed, when appropriate. When the variable had more than two categories, an ANOVA or Kruskal Wallis test was used. A p value \<0.05 was considered statistically significant.

    Time frame: Through study completion, an average of 2 year

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2028, 97 months after the start.

Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 97 months is above that.

Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion May 2025 → Dec 2028 and completion May 2028 → May 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 3, 2025
StartActual
Nov 13, 2020
Primary completionEst.
Dec 2028was May 2025
CompletionEst.
May 2031was May 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 9 sites removed
Show 4 added (4 Spain)
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Sant Joan de Déu · Esplugues de Llobregat, Spain
  • Hospital General Universitari Gregorio Marañón · Madrid, Spain
Show 9 removed
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Sant Joan de Déu · Esplugues de Llobregat, Spain
  • Hospital General de Granollers · Granollers, Spain
  • Consorci Sanitari del Maresme - Hospital de Mataró · Mataró, Spain
  • Parc Taulí Hospital Universitari · Sabadell, Spain
  • Hospital Universitari Mútua de Terrassa · Terrassa, Spain
  • Consorci Sanitari de Terrassa · Terrassa, Spain
  • Hospital Universitari Arnau de Vilanova · Lleida, Spain
Nov 10, 2026
Primary completion
May 25, 2025→Dec 2028
Nov 10, 2026
Study completion
May 2028→May 2031
Nov 10, 2026
Enrollment
200→350
Nov 10, 2026
Eligibility
3 inclusion criteria edited, 1 added, 9 removed
What changed in the criteria
Inclusion criteria
  • RemovedSickle cell disease
  • RemovedThalassemic syndromes
  • RemovedCongenital dyserythropoietic anemia
  • RemovedEnzymopathy
  • RemovedUnstable Hemoblogin / Altered oxygen affinity
  • RemovedHereditary stomatocytosis
  • RemovedHereditary pyropoikilocytosis
  • AddedSickle cell disease (SCD) Thalassaemia syndromes Congenital dyserythropoietic anaemia (CDA) Enzymopathies Unstable haemoglobin / altered oxygen affinity Hereditary stomatocytosis Hereditary pyropoikilocytosis
  • EditedHereditary spherocytosis with(HS), either severe anemia ((baseline Hb <810 g/dL or transfusion-dependent) or with an inconclusive diagnosis:
  • EditedPatient with chronic hemolytic anemiahaemolytic anaemia and a compatible red cell smear compatible, but with:
  • RemovedEMA binding test: inconclusive or negative
  • EditedEMA binding test: inconclusive or negative Genetic testing: no definitive diagnosis (VUS or no findings)
  • RemovedNot transplanted or undergoing gene therapy at the time of inclusion. Patients with graft failure without a new transplant may be included.
Nov 10, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameTo assess the prognostic value of LoRRca ektacytometry as biomarker providing information of SCD/RADs patients severityThrough study completion, an average of 2 year → Through study completion, an average of 2 years
Nov 10, 2026
Sponsor
Collaborators added: Hospital Vall d'Hebron; collaborators removed: Hospital Arnau de Vilanova, Lleida (Spain)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    4 sites added, 9 sites removed
    Show 4 added (4 Spain)
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Sant Joan de Déu · Esplugues de Llobregat, Spain
    • Hospital General Universitari Gregorio Marañón · Madrid, Spain
    Show 9 removed
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Sant Joan de Déu · Esplugues de Llobregat, Spain
    • Hospital General de Granollers · Granollers, Spain
    • Consorci Sanitari del Maresme - Hospital de Mataró · Mataró, Spain
    • Parc Taulí Hospital Universitari · Sabadell, Spain
    • Hospital Universitari Mútua de Terrassa · Terrassa, Spain
    • Consorci Sanitari de Terrassa · Terrassa, Spain
    • Hospital Universitari Arnau de Vilanova · Lleida, Spain
    Primary completion May 25, 2025→Dec 2028
    Study completion May 2028→May 2031
    Enrollment 200→350
    Eligibility 3 inclusion criteria edited, 1 added, 9 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedSickle cell disease
    • RemovedThalassemic syndromes
    • RemovedCongenital dyserythropoietic anemia
    • RemovedEnzymopathy
    • RemovedUnstable Hemoblogin / Altered oxygen affinity
    • RemovedHereditary stomatocytosis
    • RemovedHereditary pyropoikilocytosis
    • AddedSickle cell disease (SCD) Thalassaemia syndromes Congenital dyserythropoietic anaemia (CDA) Enzymopathies Unstable haemoglobin / altered oxygen affinity Hereditary stomatocytosis Hereditary pyropoikilocytosis
    • EditedHereditary spherocytosis with(HS), either severe anemia ((baseline Hb <810 g/dL or transfusion-dependent) or with an inconclusive diagnosis:
    • EditedPatient with chronic hemolytic anemiahaemolytic anaemia and a compatible red cell smear compatible, but with:
    • RemovedEMA binding test: inconclusive or negative
    • EditedEMA binding test: inconclusive or negative Genetic testing: no definitive diagnosis (VUS or no findings)
    • RemovedNot transplanted or undergoing gene therapy at the time of inclusion. Patients with graft failure without a new transplant may be included.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameTo assess the prognostic value of LoRRca ektacytometry as biomarker providing information of SCD/RADs patients severityThrough study completion, an average of 2 year → Through study completion, an average of 2 years
    Sponsor Collaborators added: Hospital Vall d'Hebron; collaborators removed: Hospital Arnau de Vilanova, Lleida (Spain)
    + 5 other changes: identifiers, verification date, description, conditions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07206095
Collaborators
Hospital Clinic of Barcelona, Institute for Bioengineering of Catalonia, Hospital Vall d'Hebron
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Nov 13, 2020
Primary completion
Dec 2028 (estimated)
Completion
May 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Mar Mañú Pereira PhD
Contact
mar.manu@vhir.org
+34 93 489 4063
Mar Mañú Pereira, PhD
principal investigator · Hospital Universitari Vall d'Hebron Institut de Recerca (VHIR)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion